FOXN2抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: K562 and Hela cell lysates, Primary antibody: P10869(FOXN2 Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P10869(FOXN2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P10869(FOXN2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

FOXN2 (Forkhead Box N2) is a member of the forkhead box (FOX) family of transcription factors, characterized by a conserved DNA-binding domain termed the "forkhead" or "winged-helix" domain. Initially identified for its role in developmental processes, FOXN2 is implicated in regulating gene expression involved in cell differentiation, proliferation, and apoptosis. It shares structural homology with FOXN1. a critical regulator of thymic epithelial development and T-cell maturation, but exhibits distinct expression patterns and functions. FOXN2 is broadly expressed in tissues, including the brain, liver, and reproductive organs, and has been linked to neurodevelopment, epithelial cell differentiation, and tissue homeostasis.

Research highlights FOXN2's dual role in cancer, acting as either a tumor suppressor or oncogene depending on context. Studies report its downregulation in hepatocellular carcinoma, lung cancer, and gliomas, where it suppresses tumor growth by modulating cell cycle progression or apoptosis-related pathways. Conversely, FOXN2 overexpression in certain malignancies, such as breast cancer, correlates with poor prognosis, suggesting context-dependent functionality. FOXN2 antibodies are essential tools for investigating these mechanisms, enabling detection of protein expression, localization (nuclear/cytoplasmic), and interaction partners via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. Commercial antibodies are typically validated for specificity against the conserved forkhead domain or unique epitopes. Current research focuses on FOXN2's regulatory networks, post-translational modifications, and potential as a therapeutic target or biomarker, underscoring its emerging significance in cancer biology and regenerative medicine.